.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 4,942,157

« Back to Dashboard

Details for Patent: 4,942,157

Title: 1-hydroxy-3-(N-methyl-N-propylamino)propane-1,1-diphosphonic acid, pharmaceutical compositions and methods of use
Abstract:The present invention provides 1-Hydroxy-3-(N-methyl-N-propylamino)propane-1,1-diphosphonic acid of formula ##STR1## wherein R is hydrogen or C.sub.1 -C.sub.4 alkyl and the pharmacologically acceptable salts thereof. The present invention also provides processes for the preparation of a diphosphonic acid of formula I and pharmaceutical compositions containing it for the treatment of diseases of the calcium metabolism.
Inventor(s): Gall; Rudi (Mannheim, DE), Bosies; Elmar (Mannheim, DE)
Assignee: Boehringer Mannheim GmbH (Mannheim, DE)
Filing Date:Jul 09, 1987
Application Number:07/071,320
Claims:1. A diphosphonate compound of the formula ##STR9## wherein R is hydrogen, and the pharmacologically acceptable salts thereof.

2. A pharmaceutical composition for the treatment or prophylaxis of calcium metabolism disturbance or disease containing an effective amount of at least one compound of claim 1 in pharmaceutically acceptable carrier.

3. A pharmaceutical composition for the treatment or prophylaxis of calcium metabolism disturbance or disease containing an effective amount in a pharmaceutically acceptable carrier of 1-hydroxy-3-(N-methyl-N-propylamino)propane-1,1-diphosphonic acid.

4. A method for the treatment or prophylaxis of calcium metabolism disturbance or disease comprising administering a pharmaceutically effective amount of the compound of claim 1.

5. A method for the treatment or prophylaxis of calcium metabolism disturbance or disease comprising administering a pharmaceutically effective amount of 1-hydroxy-3-(N-methyl-N-propylamino)propane-1,1-diphosphonic acid.

6. The method of claim 4 wherein 0.001-10 mg P/Kg of the pharmaceutically acceptable diphosphonate compound are administered per day.

7. The method of claim 5 wherein 0.01-10 mg P/Kg of the pharmaceutically acceptable disphosphonate are administered per day.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc